In Silico Identification and Biological Evaluation of Novel Selective Serum/Glucocorticoid-Inducible Kinase 1 Inhibitors Based on the Pyrazolo-Pyrimidine Scaffold
暂无分享,去创建一个
Stefano Alcaro | Anna Artese | Francesco Ortuso | Giosuè Costa | Silvia Schenone | Lorenzo Botta | Rosario Amato | Lucia D'antona | Cristina Talarico | Francesco Gigliotti | Cataldo Bianco | Francesco Trapasso | Francesca Musumeci | Nicola Perrotti | F. Musumeci | S. Schenone | F. Trapasso | L. Botta | S. Alcaro | G. Costa | A. Artese | F. Ortuso | L. D'antona | N. Perrotti | C. Bianco | R. Amato | C. Talarico | Francesco Gigliotti
[1] Simeon I. Taylor,et al. sgk: an essential convergence point for peptide and steroid hormone regulation of ENaC-mediated Na+ transport. , 2002, American journal of physiology. Cell physiology.
[2] G. Cuda,et al. Sgk1 enhances RANBP1 transcript levels and decreases taxol sensitivity in RKO colon carcinoma cells , 2013, Oncogene.
[3] Tracey Clark,et al. Design of selective, ATP-competitive inhibitors of Akt. , 2010, Journal of medicinal chemistry.
[4] A. C. Maiyar,et al. Expression of the Serum- and Glucocorticoid-inducible Protein Kinase, Sgk, Is a Cell Survival Response to Multiple Types of Environmental Stress Stimuli in Mammary Epithelial Cells* , 2003, The Journal of Biological Chemistry.
[5] C. Haft,et al. Activation of Serum- and Glucocorticoid-induced Protein Kinase (Sgk) by Cyclic AMP and Insulin* , 2001, The Journal of Biological Chemistry.
[6] Baoguang Zhao,et al. Design and synthesis of orally bioavailable serum and glucocorticoid-regulated kinase 1 (SGK1) inhibitors. , 2009, Bioorganic & medicinal chemistry letters.
[7] Won Young Tak,et al. Gene expression profile analysis in human hepatocellular carcinoma by cDNA microarray. , 2002, Molecules and cells.
[8] M. Gishizky,et al. SU6656, a Selective Src Family Kinase Inhibitor, Used To Probe Growth Factor Signaling , 2000, Molecular and Cellular Biology.
[9] C. Brullo,et al. Hit Identification and Biological Evaluation of Anticancer Pyrazolopyrimidines Endowed with Anti‐inflammatory Activity , 2010, ChemMedChem.
[10] Dana L. Miller,et al. C. Elegans Are Protected from Lethal Hypoxia by an Embryonic Diapause , 2009, Current Biology.
[11] M. Radi,et al. Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study. , 2011, Journal of medicinal chemistry.
[12] D. Kwiatkowski,et al. mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. , 2008, Molecular cell.
[13] M. Modugno,et al. Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation. , 2006, Journal of medicinal chemistry.
[14] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[15] F. Lang,et al. Sgk1 activates MDM2-dependent p53 degradation and affects cell proliferation, survival, and differentiation , 2009, Journal of Molecular Medicine.
[16] P. Visca,et al. Determination of SGK1 mRNA in non-small cell lung cancer samples underlines high expression in squamous cell carcinomas , 2012, Journal of experimental & clinical cancer research : CR.
[17] P. Cohen,et al. The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.
[18] Vito Barbieri,et al. IL-2 signals through Sgk1 and inhibits proliferation and apoptosis in kidney cancer cells , 2007, Journal of Molecular Medicine.
[19] P. Visca,et al. Determination of SGK1 mRNA in non-small cell lung cancer samples underlines high expression in squamous cell carcinomas , 2012, Journal of Experimental & Clinical Cancer Research.
[20] N. Laping,et al. Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic. , 2008, Cancer research.
[21] C. Brullo,et al. Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice. , 2007, Journal of medicinal chemistry.
[22] P. Fossa,et al. Pyrazolo[3,4-d]pyrimidines endowed with antiproliferative activity on ductal infiltrating carcinoma cells. , 2004, Journal of medicinal chemistry.
[23] K. Boini,et al. EMD638683, a Novel SGK Inhibitor with Antihypertensive Potency , 2011, Cellular Physiology and Biochemistry.
[24] Baoguang Zhao,et al. Crystal structure of the kinase domain of serum and glucocorticoid‐regulated kinase 1 in complex with AMP–PNP , 2007, Protein science : a publication of the Protein Society.
[25] Suzanne D. Conzen,et al. Glucocorticoid Receptor-mediated Protection from Apoptosis Is Associated with Induction of the Serine/Threonine Survival Kinase Gene, sgk-1 * , 2001, The Journal of Biological Chemistry.
[26] Dan Liu,et al. Identification of CISK, a new member of the SGK kinase family that promotes IL-3-dependent survival , 2000, Current Biology.
[27] Tracey Clark,et al. Synthesis and structure based optimization of novel Akt inhibitors. , 2008, Bioorganic & medicinal chemistry letters.
[28] Peter Ballard,et al. Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases. , 2013, Journal of medicinal chemistry.
[29] B. Brandhuber,et al. An ATP-Site On-Off Switch That Restricts Phosphatase Accessibility of Akt , 2012, Science Signaling.
[30] S. Conzen,et al. Glucocorticoid Receptor Antagonism as a Novel Therapy for Triple-Negative Breast Cancer , 2013, Clinical Cancer Research.
[31] R. Pearson,et al. AKT-independent PI3-K signaling in cancer – emerging role for SGK3 , 2013, Cancer management and research.
[32] Wei Wu,et al. Microarray Analysis Reveals Glucocorticoid-Regulated Survival Genes That Are Associated With Inhibition of Apoptosis in Breast Epithelial Cells , 2004, Cancer Research.
[33] H. Rodemann,et al. Inhibition of Colonic Tumor Growth by the Selective SGK Inhibitor EMD638683 , 2013, Cellular Physiology and Biochemistry.
[34] S. Schenone,et al. Pyrazolo[3,4-d]pyrimidines c-Src inhibitors reduce epidermal growth factor-induced migration in prostate cancer cells. , 2006, European journal of cancer.